The oncology reimbursement landscape continues to present ever-evolving challenges for clinicians and others that work with patients with cancer. As a response to these ongoing challenges, help is available through the NCCN Virtual Reimbursement Resource Room.
Select a cancer or supportive care indication or select a reimbursement program below to learn about reimbursement help and services available to you to help your practice mitigate reimbursement challenges.
Download the NCCN Reimbursement Resource App for Smartphones and Tablets
Download the NCCN Virtual Reimbursement Resource Room Guide
Now available for Apple and Android
smartphones and tablets! As a response to these ongoing challenges, help is available through the NCCN Reimbursement Resource App; users are able
to search for available resources and payment
Information on resources available are listed under three different tabs entitled: Search by Cancer Type or Supportive Care Indication, Search by Drug Name (brand or generic), and Search by Reimbursement or Assistance Program.
A printer-friendly 16 page resource to empower patients with cancer and their caregivers as you help them navigate the challenging reimbursement landscape.
Acute Promyelocytic Leukemia (APL)
Anaplastic Large Cell Carcinoma
Basal Cell Carcinoma
Castrate Resistant Prostate Cancer
Chronic Lymphocytic Leukemia
Chronic Myelogenous Leukemia (CML)
Gastroesophageal Junction Cancer
Gastrointestinal Stromal Tumor (GIST)
Head and Neck Cancers
Mantle Cell Lymphoma
Metastatic Breast Cancer
Metastatic Colorectal Cancer
Mycosis Fungoides/Sezary Syndrome
Neuroendocrine Tumors of Pancreatic Origin
Non-Small Cell Lung Cancer
Peripheral T-Cell Lymphoma
Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia
Prevention and Treatment of Cancer-Related Infections
Renal Cell Carcinoma
Soft Tissue Sarcoma
Abiraterone acetate (ZYTIGA®) --- ZytigaOne™ Support – http://www.zytigahcp.com/zytigaone-support#zytigaone-support and http://www.janssenprescriptionassistance.com/zytiga
Ado-trastuzumab emtansine (Kadcyla) --- Genentech Access Solutions
Afatinib (GILOTRIF®) --- Boehringer Ingelheim Solutions Plus™
Arsenic Trioxide (Trisenox®) --- Teva Oncology: CORE (Comprehensive Oncology Reimbursement Expertise)
Azacitidine for injection (Vidaza®) --- Celgene Patient Support®
Bendamustine (Treanda®) --- Teva Oncology: CORE (Comprehensive Oncology Reimbursement Expertise)
Bevacizumab (Avastin®) --- Genentech Access Solutions
Brentuximab Vedotin (ADCETRIS®) --- Seattle Genetics - SeaGen Secure
Capecitabine (Xeloda®) --- Genentech Access Solutions
Carfilzomib (Kyprolis™) --- Onyx Pharmaceuticals
Cetuximab (Erbitux®) --- Bristol-Myers Squibb Access Support®
Dasatinib (Sprycel®) --- Bristol-Myers Squibb Access Support®
Enzalutamide capsules (XTANDI) --- XTANDI Support SolutionsSM
Eribulin mesylate (HALAVEN®) --- Eisai Assistance Program (EAP)
Erlotinib (Tarceva) --- Genentech Access Solutions
Everolimus (Afinitor®) --- Patient Assistance NOW Oncology (PANO) (Novartis Oncology)
Imatinib (Gleevec®) --- Patient Assistance NOW Oncology (PANO) (Novartis Oncology)
Ipilimumab (Yervoy™) --- Bristol-Myers Squibb Access Support®
Ixabepilone (Ixempra®) --- Bristol-Myers Squibb Access Support®
Lenalidomide (Revlimid®) --- Celgene Patient Support®
Letrozole (Femara®) --- Patient Assistance NOW Oncology (PANO) (Novartis Oncology)
Nilotinib (Tasigna®) --- Patient Assistance NOW Oncology (PANO) (Novartis Oncology)
Omacetaxine Mepesuccinate (Synribo®) --- Teva Oncology: CORE (Comprehensive Oncology Reimbursement Expertise)
Opdivo® (Nivolumab™) --- Bristol-Myers Squibb Access Support®
Paclitaxel, albumin-bound (Abraxane®) --- Celgene Patient Support®
Pemetrexed for injection (Alimta®) --- Lilly PatientOne: Reimbursement & Patient Assistance Programs
Pertuzumab (Perjeta) --- Genentech Access Solutions
Regorafenib (Stivarga®) --- REACH (Resource for Expert Assistance and Care Helpline) (Bayer HealthCare Pharmaceuticals)
Rituximab (Rituxan) --- Genentech Access Solutions
Romidepsin for injection (Istodax®) --- Celgene Patient Support®
Ruxolitinib (tablets) (Jakafi®) --- IncyteCARES (Incyte Corporation)
Sorafenib tosylate (Nexavar®) --- REACH (Resource for Expert Assistance and Care Helpline) (Bayer HealthCare Pharmaceuticals)
Tbo-filgrastim (Granix™) --- Teva Oncology: CORE (Comprehensive Oncology Reimbursement Expertise)
Thalidomide (Thalomid®) --- Celgene Patient Support®
TheraSphere® (TheraSphere®) --- BTG International Inc.: Reimbursement Services
Trastuzumab (Herceptin®) --- Genentech Access Solutions
Vemurafenib (Zelboraf) --- Genentech Access Solutions
Vismodegib (Erivedge®) --- Genentech Access Solutions
Zoledronic acid (Zometa®) --- Patient Assistance NOW Oncology (PANO) (Novartis Oncology)
- Your Patients - Your Practice - Your Choice
XTANDI Support Solutions℠ is designed as a single point of contact to help patients and their loved ones understand their coverage and reimbursement options for XTANDI (enzalutamide) capsules. Astellas is firmly committed to ensuring our patients have access to XTANDI, regardless of their financial status. We are here to answer questions about your insurance coverage and options for filling your prescription in order to get you started on therapy as quickly as possible.
Flexible and integrated resources for patient access and support:
XTANDI Patient Savings Program℠
Quick Start+℠ for XTANDI
To enable rapid initiation of treatment, the Quick Start+™ program for XTANDI provides a one-time, 14-day gratis fill supply of XTANDI that requires a physician prescription. Quick Start+ is intended for new patients who have not received a coverage decision from their payer (for example, a benefit verification or prior authorization is pending) in time to start therapy in 10 business days. Quick Start+™ offers several benefits:
Astellas Access Program℠
Astellas is committed to supporting and maintaining access to medications for patients who are treated with an Astellas product.
The Astellas Access Program℠ for XTANDI is designed for patients who have no health insurance. This program provides free XTANDI to patients who qualify for enrollment based on insurance and household income status. Eligibility is determined on a patient-specific basis. XTANDI Support Solutions℠ can quickly determine whether a patient is eligible for enrollment.
If you need assistance with the Astellas eService site, XTANDI Support Solutions℠ or have any questions on coding, coverage, and reimbursement for Astellas products, please contact us between the hours of 9:00 AM and 8:00 PM ET Monday through Friday.
XTANDI Support Solutions℠
Monday – Friday, 9:00 AM – 8:00 PM ET
Phone: 1.855.8XTANDI (1.855.898.2634)
Astellas Access Services℠
P.O. Box 13185
La Jolla, CA 92039
For Full Prescribing Information please see www.Astellas.com or contact Astellas Medical Communication at 1.800.961.0018.
XTANDI and Astellas are trademarks of Astellas Pharma Inc.
XTANDI Support Solutions℠ is a component of Astellas Access Services℠.
VeriStrat® is a serum protein test that is predictive of significant differential overall survival treatment benefit between erlotinib and single-agent chemotherapy for patients with advanced NSCLC who are EGFR wild-type or whose EGFR mutation status is unknown. The test is used in patients who have progressed after or are ineligible for platinum-based doublet chemotherapy.
If you have any questions at all regarding coverage and payment, please contact the VeriStrat Support Hotline at 1.866.432.5930.
Making patient support our priority by providing a broad range of access, reimbursement and clinical support solutions for patients who are prescribed GILOTRIF® (afatinib) tablets
Call Solutions Plus at 1-877-814-3915 from 8AM to 8PM EST or online at www.bisolutionsplus.com
Bristol-Myers Squibb Oncology is committed to helping appropriate patients get access to our medications by providing reimbursement support services for healthcare professionals.
Bristol-Myers Squibb Oncology: Access Support is a comprehensive resource for Reimbursement Support Services and Patient Assistance that offers access services for patients including:
To learn more about BMS Access Support, please visit our web site or call the toll-free number to speak with a reimbursement counselor.
Monday – Friday, 8:00 AM to 8:00 PM ET
BTG is a specialist healthcare company focused on three business areas: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
BTG's Interventional Medicines include Interventional Oncology products used to treat patients with liver tumors and Interventional Vascular products used to treat patients with severe blood clots and patients with varicose veins in the great saphenous vein system of the leg.
BTG's Specialty Pharmaceutical products include antidotes to treat snake envenomation and toxicity associated with medicines used for heart conditions and cancer.
Company and product website addresses:
Celgene Patient Support® provides a dedicated, central point of contact for patients and healthcare professionals who use Celgene products. Celgene Patient Support® is a free service that helps patients and healthcare professionals navigate the challenges of reimbursement, providing information about co-pay assistance, and answering questions about obtaining Celgene products.
1.800.931.8691 or www.CelgenePatientSupport.com
Eisai's commitment to innovative solutions in disease prevention, treatment and care for the health and
well‐being of people worldwide is embodied in our human health care (hhc) mission: we give first
thoughts to patients and their families by helping to ensure access to necessary medicines.
With this in mind, the Eisai Assistance Program (EAP) provides dedicated reimbursement and access
support for patients and healthcare professionals to reduce barriers to patient access to medicines.
Specifically, EAP offers the following services:
To learn more about the Eisai Assistance Program, please visit our website or call our toll‐free number.
Phone: 1-855-EISAI-4-U (1-855-347-2448)
We Focus on Access So You Can Focus on Health
If you are concerned about paying for your Genentech medicine, we are here to help. Whether you have health care coverage or not, we can help you by:
Visit Genentech-Access.com to learn more about these programs and how to get started. To speak live with one of our Specialists, call (866) 4ACCESS/(866) 422-2377.
IncyteCARES (Connecting to Access, Reimbursement, Education and Support) was established by Incyte to assist providers, patients, and caregivers through a single point of contact with reimbursement assistance, patient access, and distribution coordination for Jakafi® (ruxolitinib).
IncyteCARES assists healthcare professionals and eligible patients with product access through a suite of services, including:
You can contact IncyteCARES, between 8 AM – 8 PM ET, by calling 1-855-4-JAKAFI (855-452-5234) or visit www.IncyteCARES.com for more information.
The Lilly PatientOne program is committed to helping eligible patients access support programs for Lilly Oncology products they are prescribed. It aims to address both financial and coverage issues for qualified uninsured, underinsured, and insured patients who are prescribed a Lilly Oncology product. PatientOne strives to offer resources, ranging from benefits investigations to financial assistance and appeals information, that provide reliable and individualized treatment support for eligible patients.
Services offered by this program include:
Patient Assistance Program
Reimbursement assistance for eligible Lilly Oncology products for an approved diagnosis
Denied claim appeals
For more information call 1-866-4PatOne (1-866-472-8663) Monday–Friday, 9AM–7PM ET or visit
Onyx 360 sets a new standard of personalized treatment support for patients, caregivers, and practices. You and your patients will have access to a dedicated Oncology Nurse Advocate and a wide range of services and support, including:
Talk to Your Patients About Onyx 360 Today.
To learn more about these services, please call 1.855.ONYX.360 (1.855.669.9360).
Patient Access Network (PAN) Foundation (866.316.7263)
The Patient Access Network Foundation is an independent, nationwide 501(c)(3) organization dedicated to providing help and hope to underinsured patients who are unable to afford the out-of-pocket expenses for their prescribed medications. Since 2004, PAN has provided over $1 billion in financial assistance to more than 500,000 people living with chronic or critical illnesses, across nearly 60 disease-specific programs. For applications and eligibility questions, call 866-316-PANF (7263). To learn more, visit www.PANFoundation.org.
Helping to make access to the therapies you need easier
Novartis Oncology is committed to helping patients living with cancer receive the medicines they need. Patient Assistance NOW Oncology offers quick and easy access to information about the broad array of support and reimbursement programs available.
You can get information about our Patient Assistance NOW Oncology support programs in 2 ways:
The REACH program assists patients with their coverage options for Nexavar® (sorafenib) tablets and Stivarga (regorafenib) tablets. Nexavar and Stivarga are distributed through designated specialty pharmacy providers (SPPs); it is not available through retail pharmacies. A REACH program counselor will work with Payers and patients to identify an SPP that will fill the Nexavar or Stivarga prescription and send it directly to the patient’s home. A REACH program counselor will also call patients to provide help in understanding insurance coverage and the Medicare Part D drug benefit and aid in finding other sources of payment for Nexavar or Stivarga. Enrollment forms are available via REACH at (866.639.2827), Monday through Friday from 9:00 AM to 8:00 PM EST, or at www.nexavar-us.com or www.stivarga-us.com. The Reimbursement Support Line team has experience with all payer types, including Medicare. Questions answered by the team typically can be classified into one of the following groups:
The On-call Team closely monitors the reimbursement environment for latest changes in Medicare, Medicaid, and private payer reimbursement and coverage polices. In addition, Bayer HealthCare Pharmaceuticals offers a patient assistance program that provides assistance to uninsured patients who meet the program requirements.
SeaGen Secure™ is a comprehensive assistance program for patients who have been prescribed ADCETRIS™ (brentuximab vedotin) and for the healthcare providers caring for them. Services offered by the program include:
Teva Oncology: CORE (Comprehensive Oncology Reimbursement Expertise) offers reimbursement support for branded Teva Oncology products. Some of the options include benefit verification, prior authorization support and customer service through the claims and appeals process. CORE also provides referrals to the Teva Cares patient assistance program.
For more information or an introductory consult please call 1-888-587-3263 or visit www.TevaCore.com
The Xofigo Access Services (XAS) program is a single point of contact to process all Xofigo (radium Ra 223 dichloride injection) orders distributed through a single designated Specialty Pharmacy Provider. XAS is a platform to provide all market access support (e.g. PAP, copay assistance, BV) for referring and treating providers, an integrated solution for order management with Cardinal Health, and data collection point to track and maintain information collected from performed provider services. A Xofigo Access Services counselor will work with the provider to help patients in understanding their individual insurance coverage and aid in finding the best support options for Xofigo. Xofigo Access Services Intake forms, Patient Assistance forms, & Benefit Verification request forms are available at www.xofigo-us.com or via phone (1-855-6Xofigo) (1-855-696-3446 Monday through Friday 9:00AM – 8:00PM EST.
The Xofigo Access Services Support includes:
Product Order and Patient Scheduling Confirmation
Copay Assistance Program
Janssen Biotech, Inc., the marketer of ZYTIGA® (abiraterone acetate), has developed ZytigaOne™ Support to help make access to ZYTIGA® simple, convenient, and easy. ZytigaOne™ Support provides focused attention and personalized support to help you and your patients with access to ZYTIGA®.
Support For You
Support For Your Patients
Click here for more information about how to enroll patients in ZytigaOne™ Support or call your personally assigned ZytigaOne™ Support Site Coordinator today.
Contact ZytigaOne™ Support
Monday – Friday, 8:00 AM – 8:00 PM ET
Before prescribing ZYTIGA® (abiraterone acetate), please see full Prescribing Information including Dosage and Administration, Warnings and Precautions available at http://www.ZYTIGAHCP.com
Industry: Provide needed information on reimbursement programs and service available
For information on participating in the NCCN Reimbursement Resource Room or other support opportunities, please contact Jennifer Tredwell at 215.690.0274 or firstname.lastname@example.org.
NCCN Member Institutions|
275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0280Copyright © 2015 National Comprehensive Cancer Network, All Rights Reserved